• Summer Poll

    Summer Poll

    With the introduction of the Corevalve Evolut R and the Sapien 3, who do you believe TAVR should be offered to?
    Intermediate-risk (STS predicted mortality 4-8%) AS patients
    Intermediate-risk AS patients older than 70 years
    Low-risk (STS predicted mortality < 4%) AS patients
    Low risk AS patients older than 70 years
    High-risk patients only
      Results